The Houston-based firm has proposed a new technology designed to produce peptides inside the human body.
Live Poll
Would you prefer a one-time treatment over recurring injections for chronic health management?
September 22, 2026
University of Houston Studied Diabetes Medication AdherenceResearchers tracked the consistency of type 2 diabetes treatment plans for over 116,000 patients.
September 22, 2026
FDA Issued Warning Letter to Houston Empower PharmacyThe regulatory agency challenged the production and prescription practices regarding compounded GLP-1 medications.
September 21, 2026
Eli Lilly Began Construction on Houston CampusThe $6.5 billion facility will produce the oral diabetes medication orforglipron.
